1 Result: Neuronetics
Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
May 09th, 2023
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69. Meanwhile, Voyager Therapeutics. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Countdown: PepsiCo, WD-40, Simply Good Foods in Focus
July 05th, 2026
Member Login